Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy
Open Access
- 8 August 2023
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 330 (6) , 505-506
Abstract
Alzheimer disease (AD), the most common form of dementia, affects more than 5 million US residents and progressively leads to a loss of memory and cognitive funKeywords
This publication has 3 references indexed in Scilit:
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Lecanemab in Early Alzheimer’s DiseaseNew England Journal of Medicine, 2023
- Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the USJAMA Neurology, 2022